Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide

Autor: Alexandra Albertsson-Lindblad, Catja Freiburghaus, Mats Jerkeman, Sara Ek

Publikováno v: Experimental Hematology & Oncology, Vol 8, Iss 1, Pp 1-5 (2019)

Abstract Background The Bruton’s Tyrosine Kinase (BTK)-inhibitor ibrutinib is highly active in mantle cell lymphoma (MCL) but may inhibit response to anti-CD20 antibody as previously shown in CLL models. We investigated how antibody-dependent cellu

Externí odkaz: https://doaj.org/article/d4b9ec25f0164c6d9d530f9370e4230e

Inhibition of Membrane-Bound BAFF by the Anti-BAFF Antibody Belimumab

Autor: Michele Vigolo, Laure Willen, Dehlia Chevalley, Pascal Schneider, Christine Kowalczyk-Quintas, Camilla Jandus

Publikováno v: Frontiers in Immunology, Vol 9 (2018)
Frontiers in immunology, vol. 9, pp. 2698
Frontiers in Immunology
Frontiers in Immunology, Vol. 9 (2018) P. 2698

B cell activating factor of the TNF family (BAFF, also known as BLyS), a cytokine that regulates homeostasis of peripheral B cells, is elevated in the circulation of patients with autoimmune diseases such as systemic lupus erythematosus (SLE). BAFF i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c9821bce666118a5e393b1df46aae96
https://www.frontiersin.org/article/10.3389/fimmu.2018.02698/full

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.